Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study

To report the efficacy of rituximab plus belimumab in patients with refractory cryoglobulinemia vasculitis (CV). Belimumab was administered intravenously at a dose 10 mg/kg on days 0, 14, 28 and then every month association 4 CV. Demographic, clinical laboratory characteristics, treatment modalities outcomes were recorded. All had type II IgM Kappa cryoglobulinemia, which associated primary Sjögren syndrome (n = 1), hepatitis C virus infection essential 2). Main manifestations CV included purpura 4), arthralgia peripheral neuropathy 3), glomerulonephritis skin ulcers 1). In all cases, and/or relapse following rituximab. Intravenous infusion along resulted rapid response four patients. Osteitis recurrent urinary tract infections occurred two showed promising results